There are currently 2781 clinical trials in Boston, Massachusetts looking for participants to engage in research studies. Trials are conducted at various facilities, including Massachusetts General Hospital, Dana Farber Cancer Institute, Beth Israel Deaconess Medical Center and Brigham and Women's Hospital. Whether you're a healthy volunteer looking to participate in paid medical research or seeking trials related to a specific condition, the city provides a diverse range of opportunities near you.
Active Surveillance, Bleomycin, Etoposide, Carboplatin or Cisplatin in Treating Pediatric and Adult Patients With Germ Cell Tumors
NCT03067181
Recruiting
This phase III trial studies how well active surveillance help doctors to monitor subjects with low risk germ cell tumors for recurrence after their tumor is removed. When the germ cell tumor has spread outside of the organ in which it developed, it is considered metastatic. Drugs used in chemotherapy, such as bleomycin, carboplatin, etoposide, and cisplatin, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them... Read More
Gender:
All
Ages:
All
Trial Updated:
06/05/2024
Locations: Tufts Children's Hospital, Boston, Massachusetts +3 locations
Conditions: Childhood Extracranial Germ Cell Tumor, Extragonadal Embryonal Carcinoma, Germ Cell Tumor, Malignant Germ Cell Tumor, Malignant Ovarian Teratoma, Stage I Ovarian Choriocarcinoma, Stage I Ovarian Embryonal Carcinoma AJCC v6 and v7, Stage I Ovarian Teratoma AJCC v6 and v7, Stage I Ovarian Yolk Sac Tumor AJCC v6 and v7, Stage I Testicular Choriocarcinoma AJCC v6 and v7, Stage I Testicular Embryonal Carcinoma AJCC v6 and v7, Stage I Testicular Yolk Sac Tumor AJCC v6 and v7, Stage II Ovarian Choriocarcinoma, Stage II Ovarian Embryonal Carcinoma AJCC v6 and v7, Stage II Ovarian Yolk Sac Tumor AJCC v6 and v7, Stage II Testicular Choriocarcinoma AJCC v6 and v7, Stage II Testicular Embryonal Carcinoma AJCC v6 and v7, Stage II Testicular Yolk Sac Tumor AJCC v6 and v7, Stage III Ovarian Choriocarcinoma, Stage III Ovarian Embryonal Carcinoma AJCC v6 and v7, Stage III Ovarian Yolk Sac Tumor AJCC v6 and v7, Stage III Testicular Choriocarcinoma AJCC v6 and v7, Stage III Testicular Embryonal Carcinoma AJCC v6 and v7, Stage III Testicular Yolk Sac Tumor AJCC v6 and v7, Stage IV Ovarian Choriocarcinoma, Stage IV Ovarian Embryonal Carcinoma AJCC v6 and v7, Stage IV Ovarian Yolk Sac Tumor AJCC v6 and v7, Testicular Mixed Choriocarcinoma and Embryonal Carcinoma, Testicular Mixed Choriocarcinoma and Teratoma, Testicular Mixed Choriocarcinoma and Yolk Sac Tumor, Stage I Testicular Seminoma AJCC v6 and v7
Register for Updates
Long-term Extension Study of Zanubrutinib (BGB-3111) Regimens in Participants With B-cell Malignancies
NCT04170283
Recruiting
The purpose of this study is to evaluate the long-term safety of zanubrutinib regimens in participants with B-cell malignancies who participated in a BeiGene parent study for zanubrutinib.
Gender:
All
Ages:
18 years and above
Trial Updated:
06/05/2024
Locations: Dana Farber Cancer Institute, Boston, Massachusetts
Conditions: B-cell Malignancies
Register for Updates
Toward Understanding Drivers of Patient Engagement With Digital Mental Health Interventions - Part II
NCT05555875
Recruiting
This study is a clinical trial that evaluates what drives patient engagement and tests the impact of two strategies-automated motivational push messaging and coach support-to improve engagement with an evidence-based mobile app intervention for depression and/or anxiety.
Gender:
All
Ages:
Between 18 years and 75 years
Trial Updated:
06/05/2024
Locations: Jessica Morrow Lipschitz, Boston, Massachusetts
Conditions: Depression, Anxiety Disorders
Register for Updates
A Dose-ranging Study in Patients With Diabetic Peripheral Neuropathic Pain (DPNP)
NCT06203002
Recruiting
Evaluation of the efficacy of LX9211 compared to placebo in reducing DPNP.
Gender:
All
Ages:
18 years and above
Trial Updated:
06/05/2024
Locations: Lexicon Investigational Site (121), Boston, Massachusetts
Conditions: Diabetic Peripheral Neuropathic Pain
Register for Updates
VOLT-AF IDE Clinical Study
NCT06223789
Recruiting
This clinical investigation is intended to demonstrate safety and effectiveness of the Volt™ Pulsed Field Ablation (PFA) Catheter Sensor Enabled™, the Volt™ PFA Generator, Agilis™ NxT Steerable Introducer Dual-Reach™, and EnSite™ X EP System EnSite™ Pulsed Field Ablation Module (for simplicity of reference this device collection will hereafter be referred to as the Volt™ PFA system) for the treatment of symptomatic, recurrent, drug-refractory paroxysmal and persistent atrial fibrillation. Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
06/05/2024
Locations: Massachusetts General Hospital, Boston, Massachusetts
Conditions: Atrial Arrhythmia, Atrial Fibrillation, Paroxysmal Atrial Fibrillation, Persistent Atrial Fibrillation
Register for Updates
Sequential Allocation Study of Music Duration
NCT04909736
Recruiting
The investigators are interested in studying the effects of varying lengths of musical exposure on patient anxiety and stress levels.
Gender:
Female
Ages:
Between 18 years and 50 years
Trial Updated:
06/05/2024
Locations: Tufts Medical Center, Boston, Massachusetts
Conditions: Anxiety, Patient Satisfaction, Music Exposure
Register for Updates
A Study To Evaluate Safety And Efficacy Of Ocrelizumab In Comparison With Fingolimod In Children And Adolescents With Relapsing-Remitting Multiple Sclerosis
NCT05123703
Recruiting
This double-blind, double-dummy study will evaluate the safety and efficacy of ocrelizumab compared with fingolimod in children and adolescents with relapsing-remitting multiple sclerosis aged between 10 and < 18 years over a duration of at least 96 weeks.
Gender:
All
Ages:
Between 10 years and 17 years
Trial Updated:
06/05/2024
Locations: Pediatric Multiple Sclerosis and Related Disorders Program at Boston Children's Hospital, Boston, Massachusetts
Conditions: Relapsing-Remitting Multiple Sclerosis
Register for Updates
Durvalumab vs Placebo With Stereotactic Body Radiation Therapy in Early Stage Unresected Non-small Cell Lung Cancer (NSCLC) Patients / Osimertinib Following SBRT in Patients With Early Stage Unresected NSCLC Harboring an EGFR Mutation
NCT03833154
Recruiting
This is a Phase III, randomized, placebo-controlled, double-blind, multi-center study assessing the efficacy and safety of durvalumab with SoC SBRT versus placebo with SoC SBRT in patients with unresected clinical Stage I/II lymph node-negative (T1 to T3N0M0) NSCLC. An additional cohort will assess Osimertinib following SBRT in patients with early stage unresected T1 to T3N0M0 NSCLC harbouring an EGFR mutation.
Gender:
All
Ages:
Between 18 years and 130 years
Trial Updated:
06/05/2024
Locations: Research Site, Boston, Massachusetts
Conditions: Carcinoma, Non-Small-Cell Lung
Register for Updates
JoLT-Ca Sublobar Resection (SR) Versus Stereotactic Ablative Radiotherapy (SAbR) for Lung Cancer
NCT02468024
Recruiting
To Determine if SAbR improves survival over SR in High Risk Operable Stage I NSCLC
Gender:
All
Ages:
18 years and above
Trial Updated:
06/05/2024
Locations: Boston Medical Center, Boston, Massachusetts
Conditions: Non-Small Cell Lung Cancer
Register for Updates
Early Parkinson's Disease Monotherapy With CVN424
NCT06006247
Recruiting
This is a multicenter, 12-week, placebo-controlled clinical trial of CVN424 150 milligrams (mg) tablets in early, untreated Parkinson's Disease (PD). Participants will be randomized in a 1:1 ratio to CVN424 150 mg or placebo at the Baseline Visit. The purpose of this study is to measure effect on motor features with CVN424 tablets compared to placebo in early, untreated PD and to evaluate the potential of CVN424 to improve motor and non-motor functions in participants with early PD who are not t... Read More
Gender:
All
Ages:
30 years and above
Trial Updated:
06/04/2024
Locations: Beth Israel Deaconess Medical Center, Boston, Massachusetts
Conditions: Parkinson's Disease
Register for Updates
A Safety and Efficacy Study of Treatment Combinations With and Without Chemotherapy in Adult Participants With Advanced Upper Gastrointestinal Tract Malignancies
NCT05329766
Recruiting
The purpose of this study is to evaluate the safety and preliminary clinical activity of treatment combinations with and without chemotherapy in participants with locally advanced unresectable or metastatic gastric, GEJ, and esophageal adenocarcinoma. Chemotherapy will consist of FOLFOX (oxaliplatin, leucovorin, fluorouracil).
Gender:
All
Ages:
18 years and above
Trial Updated:
06/04/2024
Locations: Massachusetts General Hospital, Boston, Massachusetts
Conditions: Gastrointestinal Tract Malignancies
Register for Updates
Renal Allograft Tolerance Through Mixed Chimerism - SMC/MGH
NCT04540380
Recruiting
The goal is to investigate the safety of the conditioning regimen, and its ability to induce donor/recipient lymphohematopoietic chimerism without Chimerism Transition Syndrome (CTS), which may result in donor-specific unresponsiveness (tolerance) to the renal allograft in the absence of maintenance immunosuppression.
Gender:
All
Ages:
Between 18 years and 65 years
Trial Updated:
06/04/2024
Locations: Massachusetts General Hospital, Boston, Massachusetts
Conditions: Renal Failure
Register for Updates